This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through March 4, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
3 Medical Info Systems Stocks to Buy as Industry Rebounds
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like Clover Health Investments (CLOV), Talkspace (TALK) and P3 Health Partners (PIII) are expected to gain from the new normal trends.
Clover Health Investments, Corp. (CLOV) Upgraded to Buy: Here's Why
by Zacks Equity Research
Clover Health Investments, Corp. (CLOV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are Medical Stocks Lagging Clover Health Investments (CLOV) This Year?
by Zacks Equity Research
Here is how Clover Health Investments, Corp. (CLOV) and Amedisys (AMED) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Axcella Health (AXLA) This Year?
by Zacks Equity Research
Here is how Axcella Health Inc. (AXLA) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Clover Health Investments (CLOV) This Year?
by Zacks Equity Research
Here is how Clover Health Investments, Corp. (CLOV) and Axcella Health Inc. (AXLA) have performed compared to their sector so far this year.
Clover Health Investments, Corp. (CLOV) Shows Fast-paced Momentum But Is Still a Bargain Stock
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Clover Health Investments, Corp. (CLOV) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Clover Health Investments, Corp. (CLOV) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clover Health Investments, Corp. (CLOV) delivered earnings and revenue surprises of 53.85% and 1.41%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Nextgen Healthcare (NXGN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Nextgen Healthcare (NXGN) delivered earnings and revenue surprises of 14.29% and 2.95%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Definitive Healthcare, Clover Health and Augmedix
by Zacks Equity Research
Healthcare, Clover Health and Augmedix are part of the Zacks Industry Outlook article.
3 Medical Info Systems Stocks to Consider From a Prospering Industry
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like Definitive Healthcare (DH), Clover Health Investments (CLOV) and Augmedix (AUGX) are expected to gain from new normal trends.
Fast-paced Momentum Stock Clover Health Investments, Corp. (CLOV) Is Still Trading at a Bargain
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Clover Health Investments, Corp. (CLOV) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Bear of the Day: Icahn Enterprises (IEP)
by Andrew Rocco
IEP stock is getting crushed this year as an inflated NAV, poor fundamentals, and negative headlines present obstacles.
Is Ligand Pharmaceuticals (LGND) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Ligand Pharmaceuticals (LGND) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
Is Clover Health Investments (CLOV) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Clover Health Investments, Corp. (CLOV) and Pyxis Oncology, Inc. (PYXS) have performed compared to their sector so far this year.
Clover Health Investments, Corp. (CLOV) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clover Health Investments, Corp. (CLOV) delivered earnings and revenue surprises of 21.05% and 7.29%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Biohaven Ltd. (BHVN) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
Down 22.2% in 4 Weeks, Here's Why You Should You Buy the Dip in Clover Health Investments, Corp. (CLOV)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Clover Health Investments, Corp. (CLOV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Clover Health Investments, Corp. (CLOV) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clover Health Investments, Corp. (CLOV) delivered earnings and revenue surprises of 48.39% and 3.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
10x Genomics (TXG) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of 17.78% and 1.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Clover Health Investments, Corp. (CLOV) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Clover Health Investments, Corp. (CLOV) delivered earnings and revenue surprises of 4.35% and 0.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Omnicell (OMCL) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of -1.18% and 2.37%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Signify Health (SGFY) Q2 Earnings Beat Estimates
by Zacks Equity Research
Signify (SGFY) delivered earnings and revenue surprises of 130% and 1.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Clover Health Investments, Corp. (CLOV) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clover Health Investments, Corp. (CLOV) delivered earnings and revenue surprises of 20.83% and 7.23%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Clover Health (CLOV) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Clover Health's (CLOV) first-quarter results are likely to reflect benefits from Clover Assistant management.
10x Genomics (TXG) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of -2.70% and 1.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?